- Home
- INO vs OVID Comparison
INO vs OVID Comparison
Compare INO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- OVID
- Stock Information
- Founded
- INO 1979
- OVID 2014
- Country
- INO United States
- OVID United States
- Employees
- INO N/A
- OVID N/A
- Industry
- INO Medical/Dental Instruments
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- OVID Health Care
- Exchange
- INO Nasdaq
- OVID Nasdaq
- Market Cap
- INO 136.6M
- OVID 117.3M
- IPO Year
- INO 1998
- OVID 2017
- Fundamental
- Price
- INO $2.42
- OVID $1.40
- Analyst Decision
- INO Buy
- OVID Strong Buy
- Analyst Count
- INO 5
- OVID 4
- Target Price
- INO $8.80
- OVID $3.13
- AVG Volume (30 Days)
- INO 1.1M
- OVID 5.0M
- Earning Date
- INO 11-10-2025
- OVID 11-13-2025
- Dividend Yield
- INO N/A
- OVID N/A
- EPS Growth
- INO N/A
- OVID N/A
- EPS
- INO N/A
- OVID N/A
- Revenue
- INO $182,337.00
- OVID $6,651,000.00
- Revenue This Year
- INO N/A
- OVID $1,086.57
- Revenue Next Year
- INO $14,751.49
- OVID N/A
- P/E Ratio
- INO N/A
- OVID N/A
- Revenue Growth
- INO N/A
- OVID 1070.95
- 52 Week Low
- INO $1.30
- OVID $0.24
- 52 Week High
- INO $5.80
- OVID $2.01
- Technical
- Relative Strength Index (RSI)
- INO 49.71
- OVID 43.60
- Support Level
- INO $2.36
- OVID $1.50
- Resistance Level
- INO $2.67
- OVID $1.73
- Average True Range (ATR)
- INO 0.13
- OVID 0.12
- MACD
- INO -0.01
- OVID -0.05
- Stochastic Oscillator
- INO 37.72
- OVID 5.62
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.